70 related articles for article (PubMed ID: 21737265)
1. Discovery and synthesis of a new class of opioid ligand having a 3-azabicyclo[3.1.0]hexane core. An example of a 'magic methyl' giving a 35-fold improvement in binding.
Lunn G; Banks BJ; Crook R; Feeder N; Pettman A; Sabnis Y
Bioorg Med Chem Lett; 2011 Aug; 21(15):4608-11. PubMed ID: 21737265
[TBL] [Abstract][Full Text] [Related]
2. SAR and biological evaluation of 3-azabicyclo[3.1.0]hexane derivatives as μ opioid ligands.
Lunn G; Roberts LR; Content S; Critcher DJ; Douglas S; Fenwick AE; Gethin DM; Goodwin G; Greenway D; Greenwood S; Hall K; Thomas M; Thompson S; Williams D; Wood G; Wylie A
Bioorg Med Chem Lett; 2012 Mar; 22(6):2200-3. PubMed ID: 22357342
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.
Le Bourdonnec B; Goodman AJ; Graczyk TM; Belanger S; Seida PR; DeHaven RN; Dolle RE
J Med Chem; 2006 Dec; 49(25):7290-306. PubMed ID: 17149859
[TBL] [Abstract][Full Text] [Related]
4. Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.
Micheli F; Arista L; Bertani B; Braggio S; Capelli AM; Cremonesi S; Di-Fabio R; Gelardi G; Gentile G; Marchioro C; Pasquarello A; Provera S; Tedesco G; Tarsi L; Terreni S; Worby A; Heidbreder C
J Med Chem; 2010 Oct; 53(19):7129-39. PubMed ID: 20839775
[TBL] [Abstract][Full Text] [Related]
5. Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective μ-antagonist activity.
Iyer MR; Lee YS; Deschamps JR; Dersch CM; Rothman RB; Jacobson AE; Rice KC
Eur J Med Chem; 2012 Apr; 50():44-54. PubMed ID: 22341895
[TBL] [Abstract][Full Text] [Related]
6. Elucidation of the bioactive conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of mu-opioid receptor antagonists.
Le Bourdonnec B; Goodman AJ; Michaut M; Ye HF; Graczyk TM; Belanger S; Herbertz T; Yap GP; DeHaven RN; Dolle RE
J Med Chem; 2006 Dec; 49(25):7278-89. PubMed ID: 17149858
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2006 Jan; 49(1):256-62. PubMed ID: 16392810
[TBL] [Abstract][Full Text] [Related]
8. [Binding characteristics of new synthesized opioid receptor ligands to cloned mu opioid receptors stably expressed in CHO cell].
Hu P; Ye CY; Qiu ZB; Yang HF; Zhang DC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Feb; 25(1):79-82. PubMed ID: 12905615
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.
Spetea M; Schüllner F; Moisa RC; Berzetei-Gurske IP; Schraml B; Dörfler C; Aceto MD; Harris LS; Coop A; Schmidhammer H
J Med Chem; 2004 Jun; 47(12):3242-7. PubMed ID: 15163203
[TBL] [Abstract][Full Text] [Related]
10. Receptor reserve reflects differential intrinsic efficacy associated with opioid diastereomers.
Carliss RD; Keefer JF; Perschke S; Welch S; Rich TC; Weissman AD
Pharmacol Biochem Behav; 2009 May; 92(3):495-502. PubMed ID: 19463265
[TBL] [Abstract][Full Text] [Related]
11. Mu-opioid receptor ligands lack receptor subtype selectivity in the aequorin luminescence-based calcium assay.
Fichna J; Staniszewska R; Poels J; Vanden Broeck J; Janecka A
Chem Biol Drug Des; 2007 Sep; 70(3):247-53. PubMed ID: 17718719
[TBL] [Abstract][Full Text] [Related]
12. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators.
Schlienger N; Lund BW; Pawlas J; Badalassi F; Bertozzi F; Lewinsky R; Fejzic A; Thygesen MB; Tabatabaei A; Bradley SR; Gardell LR; Piu F; Olsson R
J Med Chem; 2009 Nov; 52(22):7186-91. PubMed ID: 19856921
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
Neumeyer JL; Zhang A; Xiong W; Gu XH; Hilbert JE; Knapp BI; Negus SS; Mello NK; Bidlack JM
J Med Chem; 2003 Nov; 46(24):5162-70. PubMed ID: 14613319
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of N-phenylalkyl-substituted tramadol derivatives as novel μ opioid receptor ligands.
Shen Q; Qian YY; Xu XJ; Li W; Liu JG; Fu W
Acta Pharmacol Sin; 2015 Jul; 36(7):887-94. PubMed ID: 26051109
[TBL] [Abstract][Full Text] [Related]
16. Biaryl piperidines as potent and selective delta opioid receptor ligands.
Liras S; McHardy SF; Allen MP; Segelstein BE; Heck SD; Bryce DK; Schmidt AW; Vanase-Frawley M; Callegari E; McLean S
Bioorg Med Chem Lett; 2010 Jan; 20(2):503-7. PubMed ID: 20015649
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and pharmacological characterization of a novel, highly potent, peptidomimetic delta-opioid radioantagonist, [3H]Tyr-Tic-(2S,3R)-beta-MePhe-Phe-OH.
Birkas E; Kertesz I; Toth G; Bakota L; Gulya K; Szucs M
Neuropeptides; 2008 Feb; 42(1):57-67. PubMed ID: 18068762
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of 3-azabicyclo[3.1.0]hexane derivatives via palladium-catalyzed cyclopropanation of maleimides with N-tosylhydrazones: practical and facile access to CP-866,087.
Chen P; Zhu C; Zhu R; Lin Z; Wu W; Jiang H
Org Biomol Chem; 2017 Feb; 15(5):1228-1235. PubMed ID: 28094400
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
[TBL] [Abstract][Full Text] [Related]
20. Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties.
Tellew JE; Lanier M; Moorjani M; Lin E; Luo Z; Slee DH; Zhang X; Hoare SR; Grigoriadis DE; St Denis Y; Di Fabio R; Di Modugno E; Saunders J; Williams JP
Bioorg Med Chem Lett; 2010 Dec; 20(24):7259-64. PubMed ID: 21074436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
